Skip to main content
. 2018 Dec 5;131(23):2808–2816. doi: 10.4103/0366-6999.246072

Figure 2.

Figure 2

The impact of MRD pretransplant on clinical outcomes in MSDT settings. Patients with positive MRD pretransplant had higher CIR (50.0 ± 9.7% vs. 23.0 ± 3.2%, P = 0.028, χ2 = 4.809) (a), lower LFS (50.0 ± 9.7% vs. 77.0 ± 4.7%, P = 0.019, χ2 = 5.547) (b), and OS (50.0 ± 9.7% vs. 77.0 ± 8.5%, P = 0.019, χ2 = 5.805) (c) than those without MRD. MRD: Minimal residual disease; MSDT: Matched sibling donor transplantation; CIR: Cumulative incidence of relapse; LFS: Leukemia-free survival; OS: Overall survival.